Compare Organon & Co. Common Stock (OGN) vs Rivian Automotive, Inc. (RIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Rivian Automotive, Inc. — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Rivian Automotive, Inc. trades at $12.86 (market cap $18.75B). The key difference: Rivian Automotive, Inc. is far larger — about 5.2× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Rivian Automotive, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Rivian Automotive, Inc. for 61 Days on average.
| OGN | RIVN | |
|---|---|---|
Market Cap | $3.61B | $18.75B |
Volume | 1,808,049 | 23,581,407 |
Sector | Health | Consumer Cyclical |
52-Week High | $13.81 | $22.45 |
52-Week Low | $5.70 | $12.50 |
Typical Hold Time | 0 Days | 61 Days |
Enterprise Value | $11.03B | $18.79B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Rivian (RIVN) trades at $13.37, down 1.26% as investors react to mixed Q3 2026 delivery results. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal improving revenue trends ($5.39B in 2025) but persistent losses (-$3.65B net income). Recent news highlights record vehicle deliveries of 19,248 units in Q3 2026 but disappointment over unchanged full-year guidance.
The outlook remains challenging with significant cash burn and negative margins, though analyst consensus suggests 26% upside to the $16.89 price target. Key risks include execution on R2 production ramp, competitive EV market pressures, and path to profitability. The stock trades near analyst low targets, reflecting cautious optimism about Rivian's scaling potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →
